Browse the corpus

Hyperkalemia is a condition characterized by a serum or plasma potassium concentration exceeding the upper normal limit, typically greater than 5.0 to 5.5 mEq/L. Etiologic factors include impaired renal excretion, excessive potassium intake, and medications that disrupt potassium homeostasis, such as potassium-sparing diuretics and renin-angiotensin-aldosterone system inhibitors. Risk is increased in chronic kidney disease, adrenal insufficiency, and acute kidney injury. Hyperkalemia disturbs the resting membrane potential of excitable cells, particularly cardiac myocytes, predisposing to life-threatening arrhythmias, conduction abnormalities, and neuromuscular manifestations, including muscle weakness or paralysis. Clinical presentation varies with the absolute potassium level and the rate of change. Patients with chronic elevations, such as those with chronic kidney disease, may remain asymptomatic at higher potassium levels, whereas acute shifts can produce severe symptoms at lower concentrations. Infants exhibit higher baseline potassium levels than children and adults. Diagnosis relies on accurate measurement of serum potassium, with confirmation to exclude pseudohyperkalemia. Prompt intervention is essential to prevent fatal complications. Management strategies include membrane stabilization, intracellular potassium shifting, and enhanced potassium elimination through pharmacologic or renal therapies, tailored to the primary etiology and severity. This activity for healthcare professionals is designed to sharpen learners' skills in evaluating and managing hyperkalemia. Participants will deepen their understanding of the condition's etiology, risk factors, pathophysiology, clinical presentation, and evidence-based diagnostic and therapeutic recommendations. Enhanced competence will empower clinicians to collaborate with interprofessional teams caring for individuals with this electrolyte abnormality. Objectives: Identify the clinical and diagnostic features of hyperkalemia, integrating etiologic considerations to optimize therapeutic decision-making. Apply evidence-based, personalized approaches for managing hyperkalemia and preventing its potential sequelae. Improve patient awareness of hyperkalemia, associated risks, symptom recognition, and the role of diet, medications, and follow-up in management.

Identify the clinical and diagnostic features of hyperkalemia, integrating etiologic considerations to optimize therapeutic decision-making. Apply evidence-based, personalized approaches for managing hyperkalemia and preventing its potential sequelae. Improve patient awareness of hyperkalemia, associated risks, symptom recognition, and the role of diet, medications, and follow-up in management. Collaborate with all members of the interprofessional team, including specialists such as emergency medicine physicians, nephrologists, and internists, to provide efficient, comprehensive, and coordinated care for individuals with hyperkalemia. Access free multiple choice questions on this topic.

Hyperkalemia is a condition marked by a serum or plasma potassium concentration exceeding the upper limit of normal, typically greater than 5.0 to 5.5 mEq/L. Mild elevations are often asymptomatic, whereas severe hyperkalemia can precipitate life-threatening cardiac arrhythmias, muscle weakness, or paralysis. Clinical manifestations generally appear at levels above 6.0 mEq/L. However, the rate of change exerts greater influence than absolute values. Patients with chronic hyperkalemia, such as those with renal impairment, may tolerate higher potassium concentrations without symptoms, whereas acute shifts in potassium can induce severe manifestations at lower levels. Baseline potassium concentrations are higher in infants compared with children and adults. Pseudohyperkalemia is a spurious elevation in measured potassium, commonly resulting from specimen collection, handling, hemolysis, or thrombocytosis. Serum potassium should be confirmed prior to the initiation of aggressive therapy when elevations lack a clear explanation. True hyperkalemia arises from increased potassium intake, transcellular shifts of intracellular potassium, or impaired renal excretion. Therapeutic urgency is determined by the severity of clinical manifestations, measured potassium levels, and underlying etiology.[1][2]

Pseudohyperkalemia The most common apparent cause of hyperkalemia is pseudohyperkalemia, which does not reflect true serum potassium concentrations. Pseudohyperkalemia frequently results from hemolysis during specimen collection, releasing intracellular potassium into the serum.[3] Hemolysis occurs more often when a syringe is used compared with a vacuum device. Additional risk factors include prolonged tourniquet application and excessive fist-pumping during venipuncture. Specimens from patients with leukocytosis or thrombocytosis are also prone to falsely elevated potassium measurements. Increased Potassium Intake Excessive dietary potassium is an uncommon cause of hyperkalemia in adults with normal renal function but can contribute significantly in patients with impaired kidney function. High-potassium foods include dried fruits, seaweed, nuts, molasses, avocados, lima beans, potatoes, spinach, tomatoes, broccoli, beets, carrots, squash, kiwis, mangoes, oranges, bananas, cantaloupe, and red meats. (Source: National Kidney Foundation, 2023) Intravenous agents, such as potassium-containing fluids, total parenteral nutrition, potassium-rich medications, and massive blood transfusions, may also increase serum potassium levels. While these sources are generally well tolerated in patients with intact potassium homeostasis, they can precipitate hyperkalemia in individuals with renal impairment or other predisposing conditions. Intracellular Potassium Shifts Cellular injury can release substantial intracellular potassium into the extracellular space. Possible causes include rhabdomyolysis resulting from crush injury, excessive exercise, and hemolytic processes. Metabolic acidosis may also induce potassium shifts without direct red cell injury. This condition most commonly arises from decreased effective arterial blood volume. Sepsis or dehydration may lead to hypotension and reduced tissue perfusion, resulting in metabolic acidosis and secondary hyperkalemia. Insulin deficiency, as seen in diabetic ketoacidosis, may provoke marked extracellular potassium shifts, elevating serum potassium despite total body potassium depletion. Certain medications, including succinylcholine, can cause acute hyperkalemia, particularly in individuals with upregulated receptors due to subacute neuromuscular disease.

Insulin deficiency, as seen in diabetic ketoacidosis, may provoke marked extracellular potassium shifts, elevating serum potassium despite total body potassium depletion. Certain medications, including succinylcholine, can cause acute hyperkalemia, particularly in individuals with upregulated receptors due to subacute neuromuscular disease. Tumor lysis syndrome (TLS), often observed in patients undergoing chemotherapy for hematologic malignancies, can precipitate rapid hyperkalemia from massive cellular breakdown.[4] Hyperkalemic periodic paralysis, a rare autosomal dominant disorder, results from impaired skeletal muscle sodium channel function, leading to extracellular potassium shifts. Impaired Potassium Excretion Acute and chronic kidney disease are common causes of hyperkalemia. Elevations in serum potassium typically do not occur until the glomerular filtration rate declines below 30 mL/min. Hyperkalemia may result from primary renal dysfunction or secondary factors such as acute volume depletion due to dehydration, hemorrhage, or reduced effective circulating blood volume associated with congestive heart failure or cirrhosis. Tubular dysfunction, including aldosterone deficiency or insensitivity, can further impair potassium excretion and contribute to hyperkalemia.

Hyperkalemia is uncommon in the general population, occurring in fewer than 5% of individuals worldwide, but it may affect up to 10% of hospitalized patients. The majority of cases are attributable to medications and renal insufficiency in hospitalized populations. Additional risk factors in inpatients include diabetes, malignancy, extremes of age, and metabolic acidosis. Hyperkalemia is rare in children but may occur in up to 50% of premature infants. Male sex is associated with a higher incidence, potentially due to greater muscle mass, higher rates of rhabdomyolysis, and increased prevalence of neuromuscular disorders. Other contributing factors include non-Black race and advanced age.[5] The empirical use of angiotensin-converting enzyme inhibitors carries a risk of inducing hyperkalemia, particularly in high-risk populations, such as patients with diabetes, heart failure, or peripheral vascular disease.[6]

Potassium is predominantly an intracellular cation. Total body potassium stores range from 50 to 75 mEq/kg body weight, corresponding to approximately 3,000 mEq.[7] Cellular potassium is maintained by the sodium-potassium adenosine triphosphatase (ATPase) pump, which exchanges intracellular sodium for extracellular potassium in a 3:2 ratio. This mechanism establishes an intracellular potassium concentration of approximately 140 mEq/L, compared with 4 to 5 mEq/L in the extracellular fluid. The majority of potassium is excreted via the kidneys, with approximately 10% eliminated in sweat and stool. Renal potassium excretion occurs primarily in the distal convoluted tubules and cortical collecting ducts, where secretion is tightly regulated to maintain overall potassium homeostasis. Several factors influence renal potassium excretion. Aldosterone increases potassium secretion in the distal nephron. Diuretics that deliver sodium to the distal tubule enhance potassium excretion. Genetic regulators, such as WNK1 and WNK4, modulate distal tubular potassium handling. Elevated serum potassium concentrations stimulate renal potassium secretion. Increased urine flow, as occurs during osmotic diuresis, also promotes potassium excretion. Additionally, the presence of negatively charged ions, such as bicarbonate, in the distal tubule facilitates potassium secretion. Hyperkalemia arises through multiple mechanisms that increase extracellular potassium or reduce renal potassium excretion. The following table summarizes common causes according to these physiological mechanisms. Table Table. Causes and Mechanisms of Hyperkalemia.

Most patients with mild-to-moderate hyperkalemia are relatively asymptomatic. Elevated serum potassium is frequently detected during screening in patients presenting with nonspecific complaints or being evaluated for electrolyte disturbances secondary to infection, dehydration, or hypoperfusion. Possible etiologies include renal disease, diabetes, chemotherapy, major trauma, crush injury, and muscle injury consistent with rhabdomyolysis. Medications and exogenous potassium sources that may predispose to hyperkalemia include digoxin, potassium-sparing diuretics, nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, intravenous potassium, total parenteral nutrition, potassium penicillin, and succinylcholine. Patients may report weakness, fatigue, palpitations, or syncope. Physical examination may reveal hypertension and edema in the context of renal disease. Signs of hypoperfusion may be present. Muscle tenderness may indicate rhabdomyolysis, whereas jaundice may suggest hemolytic conditions. Neuromuscular manifestations can include generalized muscle weakness, flaccid paralysis, and depressed deep tendon reflexes.

The initial diagnostic evaluation for suspected hyperkalemia should include an electrocardiogram (ECG), as the most life-threatening complication is cardiac dysrhythmia, which can result in sudden death. Serum potassium elevations produce ECG changes in a dose-dependent manner, as follows: K = 5.5 to 6.5 mEq/L: Tall, peaked T waves K = 6.5 to 7.5 mEq/L: Flattening or loss of P waves K = 7 to 8 mEq/L: Widening of the QRS complex K = 8 to 10 mEq/L: Severe arrhythmias, sine-wave pattern, and potential progression to asystole The rate of increase in serum potassium exerts a greater influence on cardiac manifestations than the absolute potassium level. Patients with chronic hyperkalemia may exhibit relatively normal ECG tracings despite markedly elevated serum potassium concentrations, whereas individuals experiencing acute potassium shifts may demonstrate significant ECG abnormalities at comparatively lower levels. Characteristic ECG findings in hyperkalemia include small or absent P waves, prolongation of the PR interval, augmented R waves, widening of the QRS complex, and peaked T waves. Additional laboratory testing should include serum blood urea nitrogen and creatinine to assess renal function, as well as urinalysis to screen for underlying renal disease. Measurement of urine potassium, sodium, and osmolality may further aid in identifying the etiology. Serum calcium should be evaluated in individuals with renal impairment, as hypocalcemia can exacerbate the cardiac effects of hyperkalemia. A complete blood count is recommended to detect leukocytosis or thrombocytosis. Serum glucose and blood gas analysis should be obtained in patients with diabetes or suspected metabolic acidosis. Lactate dehydrogenase is indicated when hemolysis is suspected. Creatine phosphokinase and urine myoglobin should be measured in cases of suspected rhabdomyolysis. Uric acid and phosphorus levels should be assessed in patients at risk for TLS. Serum digoxin levels should be checked in patients receiving digoxin, as toxicity may contribute to hyperkalemia. In the absence of an identifiable cause, evaluation of cortisol and aldosterone may be warranted to assess for mineralocorticoid deficiency.

A complete blood count is recommended to detect leukocytosis or thrombocytosis. Serum glucose and blood gas analysis should be obtained in patients with diabetes or suspected metabolic acidosis. Lactate dehydrogenase is indicated when hemolysis is suspected. Creatine phosphokinase and urine myoglobin should be measured in cases of suspected rhabdomyolysis. Uric acid and phosphorus levels should be assessed in patients at risk for TLS. Serum digoxin levels should be checked in patients receiving digoxin, as toxicity may contribute to hyperkalemia. In the absence of an identifiable cause, evaluation of cortisol and aldosterone may be warranted to assess for mineralocorticoid deficiency. Since pseudohyperkalemia is common, serum potassium elevations in asymptomatic patients without characteristic ECG changes should be confirmed. Aggressive therapy should not be initiated until the potassium elevation is verified.

The urgency of hyperkalemia management depends on the rate of potassium elevation, absolute serum potassium concentration, severity of symptoms, and the underlying etiology.[9][10][11] Patients who require aggressive intervention include those presenting with neuromuscular weakness, paralysis, ECG abnormalities, serum potassium levels exceeding 5.5 mEq/L in the setting of ongoing risk, and confirmed hyperkalemia of 6.5 mEq/L. Initial management involves immediate discontinuation of exogenous potassium sources and concurrent treatment of any reversible underlying cause. Calcium therapy stabilizes cardiac membranes and should be administered first in cases of hyperkalemia-associated arrhythmias or ECG changes. Although calcium does not reduce serum potassium, it serves as first-line therapy for cardiac toxicity. Calcium chloride contains 3 times more elemental calcium than calcium gluconate but is more irritating to peripheral veins and carries a higher risk of tissue necrosis if extravasation occurs. Consequently, this formulation is typically reserved for central venous or peripheral administration during cardiac arrest. Calcium gluconate is generally preferred as the initial agent in patients with evidence of cardiac toxicity.[12] Calcium should not be administered in bicarbonate-containing fluids to avoid precipitation of calcium carbonate. Insulin, with or without glucose in hyperglycemic patients, shifts potassium into cells, lowering serum potassium levels effectively.[13] A common regimen consists of 10 units of regular insulin administered with 50 mL of 50% dextrose (D50), with careful monitoring for hypoglycemia. Continuous infusion of 10% dextrose at 50 to 75 mL/hour may reduce the risk of hypoglycemia compared with bolus administration of 50% dextrose. β2-adrenergic agonists, such as albuterol, promote intracellular potassium shifts.[14] Effective therapy requires doses higher than those typically used for bronchodilation. Sodium bicarbonate infusion may be beneficial in patients with metabolic acidosis, whereas bolus dosing is less effective. Intravenous epinephrine is not recommended for hyperkalemia management due to an increased risk of inducing angina.

β2-adrenergic agonists, such as albuterol, promote intracellular potassium shifts.[14] Effective therapy requires doses higher than those typically used for bronchodilation. Sodium bicarbonate infusion may be beneficial in patients with metabolic acidosis, whereas bolus dosing is less effective. Intravenous epinephrine is not recommended for hyperkalemia management due to an increased risk of inducing angina. Loop and thiazide diuretics may enhance renal potassium excretion. These agents may be administered in nonoliguric, volume-overloaded patients but should not be used as monotherapy in symptomatic hyperkalemia. In individuals with hypervolemia and preserved renal function, such as those with congestive heart failure, 40 mg of intravenous furosemide is administered every 12 hours or infused continuously. In patients with euvolemia or hypovolemia and preserved renal function, isotonic saline is provided as needed before administering 40 mg intravenous furosemide, which may be given every 12 hours or infused continuously. Gastrointestinal cation exchangers may be useful, particularly in patients with renal insufficiency who are not candidates for immediate dialysis. Sodium polystyrene sulfonate, historically a mainstay treatment, has seen reduced use owing to questionable efficacy and potential gastrointestinal complications such as colonic necrosis in older adults. When employed due to a lack of alternatives, this agent should not be coadministered with sorbitol, which increases the risk of toxicity.[15] Newer cation exchangers, such as patiromer and sodium zirconium cyclosilicate, may be used to reduce serum potassium acutely.[16][17] Hemodialysis is the definitive treatment for patients with end-stage renal disease or severe renal impairment. Therapeutic interventions carry potential complications, including hypokalemia, failure to adequately control hyperkalemia, hypocalcemia secondary to bicarbonate therapy, hypoglycemia induced by insulin, metabolic alkalosis from bicarbonate administration, and volume depletion associated with diuretic use.

Multiple disease states and injuries can disrupt potassium homeostasis, increasing the risk of hyperkalemia. The following etiologies represent common clinical scenarios in which potassium elevations are likely: Acute tubular necrosis Congenital adrenal hyperplasia Digitalis toxicity Electrical burn injuries Head trauma Hypocalcemia Metabolic acidosis Rhabdomyolysis Thermal burns TLS A systematic approach to diagnosing hyperkalemia allows clinicians to distinguish true potassium elevation from pseudohyperkalemia and determine the underlying mechanism. Timely recognition of the cause facilitates targeted management and improves patient outcomes.

The prognosis is favorable for patients with mild, transient hyperkalemia when the underlying cause is promptly identified and treated. In contrast, acute and severe hyperkalemia can precipitate life-threatening cardiac arrhythmias, with mortality rates approaching 2/3 if not rapidly managed. Hyperkalemia constitutes an independent risk factor for mortality among hospitalized patients. Individuals with chronic conditions, such as end-stage renal disease, require ongoing laboratory monitoring to maintain safe serum potassium concentrations.[18][19]

Complications of hyperkalemia encompass both muscular and cardiac effects, including generalized weakness, paralysis, and arrhythmias. Severe elevations in potassium can precipitate sudden cardiac arrest if not promptly managed.

Dietary potassium restriction is generally unnecessary except in individuals with severe hyperkalemia or chronic kidney disease. Patients who have comorbid conditions or are taking medications that predispose them to hyperkalemia should receive counseling regarding regular monitoring of serum urea and electrolytes, as recommended by the treating physician.

The management of hyperkalemia requires an interprofessional team due to its potential to induce life-threatening cardiac arrhythmias and severe neuromuscular weakness. The underlying etiology must be addressed following diagnosis. Continuous cardiac monitoring is essential, and nursing staff should recognize early ECG manifestations of hyperkalemia, which often precede clinical deterioration. Pharmacists ensure discontinuation of nephrotoxic agents and medications that elevate serum potassium, communicating findings promptly to the clinical team. Nursing personnel conduct ongoing monitoring, detect signs of worsening hyperkalemia, and notify the team immediately for intervention. Effective interprofessional communication and meticulous documentation are critical to ensure all team members operate from current patient data. Consultation with a nephrologist is recommended in cases of severe hyperkalemia. Cardiologist involvement is indicated when ECG changes are present. Potassium-lowering therapies should be administered continuously, with uninterrupted cardiac monitoring until serum potassium stabilizes. Dietitians provide patient education regarding a low-potassium diet, and patients with renal impairment require continued follow-up with nephrology. Coordinated efforts among all team members are essential to minimize morbidity and prevent life-threatening complications associated with hyperkalemia.